Entero Therapeutics, Inc. (ENTO) Stock Analysis

Entero Therapeutics, Inc. (ENTO) is a publicly traded company in the HEALTHCARE sector. It trades at $6.80. This page summarizes the public market data, fundamentals, and frequently asked questions for ENTO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About Entero Therapeutics, Inc.

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boca Raton, Florida, focused on advancing innovative, orally administered therapies to address unmet needs in gastrointestinal diseases. Leveraging its proprietary technology platform, Entero aims to develop targeted treatments that improve patient outcomes and enhance quality of life. With a commitment to scientific excellence and patient-centered solutions, the company is poised to make significant contribution...

GNG Research Analysis

GNG Research scores Entero Therapeutics, Inc. (ENTO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ENTO.

Frequently Asked Questions

Does ENTO pay dividends?

Entero Therapeutics, Inc. (ENTO) does not currently pay a regular dividend.